These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 31625395

  • 41. Does the Addition of Vasopressin to Catecholamine Vasopressors Affect Outcomes in Patients With Distributive Shock?
    Roumpf SK, Hunter BR.
    Ann Emerg Med; 2019 Jul; 74(1):153-155. PubMed ID: 30446352
    [No Abstract] [Full Text] [Related]

  • 42. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study).
    Póvoa PR, Carneiro AH, Ribeiro OS, Pereira AC, Portuguese Community-Acquired Sepsis Study Group.
    Crit Care Med; 2009 Feb; 37(2):410-6. PubMed ID: 19114885
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Vasopressor therapy in critically ill patients with shock.
    Russell JA.
    Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.
    Russell JA, Vincent JL, Kjølbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre PF, Grundemar L.
    Crit Care; 2017 Aug 15; 21(1):213. PubMed ID: 28807037
    [Abstract] [Full Text] [Related]

  • 49. Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis.
    Wu Z, Zhang S, Xu J, Xie J, Huang L, Huang Y, Yang Y, Qiu H.
    Shock; 2020 Jan 15; 53(1):50-57. PubMed ID: 31008869
    [Abstract] [Full Text] [Related]

  • 50. Vasopressin in the ICU.
    Holmes CL, Walley KR.
    Curr Opin Crit Care; 2004 Dec 15; 10(6):442-8. PubMed ID: 15616384
    [Abstract] [Full Text] [Related]

  • 51. Narrative Review of Controversies Involving Vasopressin Use in Septic Shock and Practical Considerations.
    Der-Nigoghossian C, Hammond DA, Ammar MA.
    Ann Pharmacother; 2020 Jul 15; 54(7):706-714. PubMed ID: 31958982
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. The Therapeutic Role of Vasopressin on Improving Lactate Clearance During and After Vasogenic Shock: Microcirculation, Is It The Black Box?
    Barzegar E, Ahmadi A, Mousavi S, Nouri M, Mojtahedzadeh M.
    Acta Med Iran; 2016 Jan 15; 54(1):15-23. PubMed ID: 26853286
    [Abstract] [Full Text] [Related]

  • 54. Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study.
    Blankenship CR, Betthauser KD, Hencken LN, Maamari JA, Goetz J, Giacomino BD, Gibson GA.
    Ann Pharmacother; 2024 Oct 15; 58(10):1003-1012. PubMed ID: 38303571
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
    Heavner MS, McCurdy MT, Mazzeffi MA, Galvagno SM, Tanaka KA, Chow JH.
    J Intensive Care Med; 2021 Jun 15; 36(6):635-645. PubMed ID: 32223515
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.